These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 9308756)

  • 61. Soluble crosslinked fibrin(ogen) polymers.
    Selmayr E; Müller-Berghaus G
    Thromb Haemost; 1985 Dec; 54(4):804-7. PubMed ID: 4089815
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of the fibrin D-dimer in screening for coagulation abnormalities in preeclampsia.
    Trofatter KF; Howell ML; Greenberg CS; Hage ML
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):435-40. PubMed ID: 2915868
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
    Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
    Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Plasma levels of soluble fibrin in patients with disseminated intravascular coagulation].
    Wada H; Takeda Y; Sakakura M; Watanabe R; Nakazaki T; Shiku H; Nishioka J; Nobori T
    Rinsho Byori; 2001 Aug; 49(8):813-7. PubMed ID: 11573293
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Progressive exposure of E-neoantigen associated with degradation of crosslinked fibrin by plasmin in vitro.
    Stegnar M; Chen JP
    Thromb Haemost; 1984 Dec; 52(3):315-20. PubMed ID: 6241755
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.
    Raut S; Gaffney PJ
    Thromb Haemost; 1996 Jul; 76(1):56-64. PubMed ID: 8819252
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Molecular markers of hemostatic-mechanisms--plasmin-alpha 2 plasmin inhibitor complex].
    Kawai Y; Watanabe K
    Rinsho Byori; 1989 Mar; 37(3):248-55. PubMed ID: 2526263
    [No Abstract]   [Full Text] [Related]  

  • 68. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases.
    Shibata T; Magari Y; Kamberi P; Ishii T; Tomo T; Yasumori R; Nasu M
    Clin Nephrol; 1995 Aug; 44(2):91-5. PubMed ID: 8529315
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
    Carroll RC; Lockhart MS; Taylor FB
    J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immune responses to the cleavage-associated neoantigens of fibrinogen in man. Identification and characterization of humoral antibodies specific for cleavage fragments.
    Plow EF; Edgington TS
    J Clin Invest; 1975 Dec; 56(6):1509-18. PubMed ID: 53241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of the factors contributing to fibrin-dependent plasminogen activation.
    Mosesson MW; Siebenlist KR; Voskuilen M; Nieuwenhuizen W
    Thromb Haemost; 1998 Apr; 79(4):796-801. PubMed ID: 9569195
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Disseminated intravascular coagulation and a negative D-dimer test.
    Constantinescu AA; Berendes PB; Levin MD
    Neth J Med; 2007 Nov; 65(10):398-400. PubMed ID: 18057464
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Measurement of autoantibodies against fibrinogen and fibrin degradation products by enzyme-linked immunoassay.
    Whitaker AN; McFarlane JR; Rowe EA; Lee K; Masci PP
    Thromb Haemost; 1985 Feb; 53(1):80-5. PubMed ID: 3992524
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation.
    Madoiwa S; Tanaka H; Nagahama Y; Dokai M; Kashiwakura Y; Ishiwata A; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
    Thromb Res; 2011 Apr; 127(4):349-55. PubMed ID: 21236472
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Incidence and clinical significance of elevated fibrin(ogen) degradation product and/or D-dimer levels in liver cirrhosis patients.
    Cioni G; Cristani A; Mussini C; Grandi S; Pentore R; Zeneroli ML; Tizzanini W; Zagni G; Ventura E
    Ital J Gastroenterol; 1990 Apr; 22(2):70-4. PubMed ID: 2131934
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [The significance of the levels of D-dimer in thrombotic conditions].
    Roul C; Aillaud MF; Elias A; Bouvier JL; Serradimigni A; Juhan-Vague I
    Ann Biol Clin (Paris); 1988; 46(9):730-3. PubMed ID: 2851949
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fibrin monomer complexes (SFMC) after substitution of antithrombin III (AT III) in consumption coagulopathy.
    Töpfer G; Ehrhardt W; Dornheim G; Seifert A; Schmidt LH; Senger C; Funke U; Schulze M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):581-5. PubMed ID: 2465977
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance.
    Adamson AS; Francis JL; Witherow RO; Snell ME
    Ann R Coll Surg Engl; 1993 Mar; 75(2):100-4. PubMed ID: 7682795
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Measurement of FDP-D-dimer in DIC and pre-DIC].
    Takagi M; Wada H; Tanigawa M; Iwasaki E; Deguchi A; Mori Y; Suzuki H; Ohkubo I; Endou T; Deguchi K
    Rinsho Byori; 1990 Jul; 38(7):806-12. PubMed ID: 2205744
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Progress in the measurement of circulating fibrinogen derivatives.
    Wilner GD
    Prog Clin Pathol; 1984; 9():15-45. PubMed ID: 6229812
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.